<DOC>
	<DOCNO>NCT02689284</DOCNO>
	<brief_summary>This main purpose clinical study learn safety activity margetuximab pembrolizumab combination treatment patient HER2+ gastric gastroesophageal junction cancer .</brief_summary>
	<brief_title>Combination Margetuximab Pembrolizumab Advanced , Metastatic HER2 ( + ) Gastric Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>Detailed Description : Both margetuximab pembrolizumab monoclonal antibody use combination treat HER2+ gastric gastroesophageal junction cancer . This study two part : Dose Escalation Dose Expansion . The Dose Escalation phase study evaluate safety escalate dos combination treatment . The Dose Expansion phase evaluate safety activity combination final dose schedule define .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Signed write informed consent . 2 . Age ≥ 18 year old . 3 . Unresectable locally advanced metastatic histologically proven HER2+ gastroesophageal junction ( GEJ ) gastric adenocarcinoma . 4 . HER2+ 3+ IHC insitu hybridation ( ISH ) amplify . 5 . Have receive prior treatment trastuzumab . 6 . Have receive treatment least one line cytotoxic chemotherapy metastatic setting . 7 . Resolution chemotherapy , immunotherapy radiationrelated toxicity . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 9 . Life expectancy ≥ 12 week . 10 . Measurable disease per RECIST 1.1 criterion . 11 . Archival newly obtain tissue sample tumor lesion . 12 . Adequate organ function determine follow laboratory parameter : 1 . Heme : Plt Ct ≥ 100 x 103/µL , ANC ≥ 1.5 x 103/µL , Hemoglobin ≥ 9 g/dL 2 . Chemistry : ALT/AST ≤ 3.0 x ULN , TBili ≤1.5 x ULN , Cr &lt; 2 mg/dL 13 . Female patient childbearing potential must negative pregnancy test agree use two form acceptable contraceptive measure time consent 120 day discontinuation study drug administration . 14 . Male patient partner childbearing potential must use barrier contraception . 1 . Patients symptomatic central nervous system ( CNS ) metastases . 2 . Patients history know suspect autoimmune disease specific exception vitiligo , atopic dermatitis , psoriasis require systemic treatment . 3 . History prior allogeneic bone marrow , stemcell solid organ transplantation . 4 . Treatment systemic antineoplastic therapy , investigational therapy within 3 week prior initiation study drug . 5 . Treatment radiation therapy within 3 week prior initiation study drug administration . 6 . Treatment corticosteroid ( ≥10 mg per day prednisone equivalent ) immune suppressive drug within 14 day prior initiation study drug administration . 7 . History clinicallysignificant cardiovascular disease . 8 . Clinicallysignificant pulmonary compromise , include requirement supplemental oxygen use maintain adequate oxygenation . 9 . Presence active pneumonitis 10 . Clinicallysignificant gastrointestinal disorder , perforation , gastrointestinal bleeding , diverticulitis . 11 . Evidence active viral , bacterial , systemic fungal infection . 12 . Known positive test human immunodeficiency virus ( HIV ) history acquire immune deficiency syndrome ( AIDS ) . 13 . Known history positive test hepatitis B hepatitis C infection . 14 . Second primary invasive malignancy remission great 2 year . 15 . Known hypersensitivity recombinant protein , polysorbate 80 excipient contain drug vehicle formulation margetuximab pembrolizumab . 16 . Female patient breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Stomach Cancer</keyword>
	<keyword>Gastroesophageal Junction</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Cancer Stomach</keyword>
	<keyword>Cancer Stomach</keyword>
	<keyword>Stomach</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Keytruda</keyword>
	<keyword>HER2+</keyword>
	<keyword>GEJ</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Margetuximab</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Human epidermal growth factor receptor 2</keyword>
	<keyword>Human epidermal growth factor receptor 2-positive</keyword>
	<keyword>gastroesophageal junction cancer</keyword>
	<keyword>Pembro</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD</keyword>
	<keyword>Tumor</keyword>
	<keyword>Cancer</keyword>
</DOC>